New Report Covers Fibroblast Growth Factor Receptor 2Keratinocyte Growth Factor Receptor-Pipeline Review, H1 2016

Fibroblast Growth Factor Receptor 2Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Complete report available @ Fibroblast Growth Factor Receptor 2Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1-Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report reviews key players involved in Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

Advenchen Laboratories, LLC Amgen Inc. ArQule, Inc. Astellas Pharma Inc. AstraZeneca Plc AVEO Pharmaceuticals, Inc. Batu Biologics, Inc. Bayer AG Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Celon Pharma Sp. z o.o. Daiichi Sankyo Company, Limited Debiopharm International SA Eddingpharm Eisai Co., Ltd. Eli Lilly and Company Hutchison MediPharma Limited Incyte Corporation Johnson & Johnson Kaken Pharmaceutical Co., Ltd. Les Laboratoires Servier SAS Nobelpharma Co., Ltd. Novartis AG Principia Biopharma Inc. Vichem Chemie Research Ltd.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###